Table 2.
Treatment effects for canagliflozin 300 mg and dapagliflozin 10 mga
| Parameter | Canagliflozin 300 mg | Dapagliflozin 10 mg |
|---|---|---|
| Clinical parameters | ||
| HbA1c, % | – 0.79 | – 0.41 |
| SBP, mmHg | – 5.4 | – 3.7 |
| BMI, kg/m2 | – 0.8 | – 0.7 |
| Total cholesterol, mmol/L (mg/dL) | 0.27 (10.4) | 0.14 (5.5) |
| LDL-C, mmol/L (mg/dL) | 0.21 (8.0) | 0.13 (5.1) |
| HDL-C, mmol/L (mg/dL) | 0.11 (4.4) | 0.09 (3.6) |
| Triglycerides, mmol/L (mg/dL) | – 0.13 (– 11.9) | – 0.18 (– 16.1) |
| Hypoglycemia events, per patient-year of exposure | ||
| Nonsevere symptomatic | 0.050 | 0.050 |
| Severe | 0.001 | 0.001 |
| AEs, per patient-year of exposure | ||
| Male genital mycotic infection | 0.067 | 0.068 |
| Female genital mycotic infection | 0.138 | 0.129 |
| Lower UTI | 0.079 | 0.087 |
| Upper UTI | 0.001 | 0.003 |
| Volume depletion-related AEs | 0.018 | 0.016 |
| Osmotic diuresis-related AEs | 0.038 | 0.056 |
| Discontinuation rate associated with AEs in the first year, % | 5.2 | 5.2 |
AE adverse event, BMI body mass index, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, NMA network meta-analysis, SBP systolic blood pressure, UTI urinary tract infection
aData for treatment effects were sourced from a 26-week NMA of anti-hyperglycemic agents, which included canagliflozin and dapagliflozin, in dual therapy with metformin [17]; for parameters not available in the NMA (i.e., hypoglycemia, AE rates, lipids), data were assumed based on a pooled analysis of two canagliflozin trials [51, 52]